186 related articles for article (PubMed ID: 5435787)
1. Interaction of plasma kallikrein with the C1 inhibitor.
Gigli I; Mason JW; Colman RW; Austen KF
J Immunol; 1970 Mar; 104(3):574-81. PubMed ID: 5435787
[No Abstract] [Full Text] [Related]
2. A new complement inhibitor in guinea pig serum.
Okada H; Kawachi S; Nishioka K
Jpn J Exp Med; 1969 Oct; 39(5):527-31. PubMed ID: 5309564
[No Abstract] [Full Text] [Related]
3. C3 inactivator of man. I. Hemolytic measurement by the inactivation of cell-bound C3.
Ruddy S; Austen KF
J Immunol; 1969 Mar; 102(3):533-43. PubMed ID: 5813010
[No Abstract] [Full Text] [Related]
4. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress.
Cugno M; Zanichelli A; Foieni F; Caccia S; Cicardi M
Trends Mol Med; 2009 Feb; 15(2):69-78. PubMed ID: 19162547
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of plasma kallikrein by C1-inhibitor: role of endothelial cells and the amino-terminal domain of C1-inhibitor.
Ravindran S; Grys TE; Welch RA; Schapira M; Patston PA
Thromb Haemost; 2004 Dec; 92(6):1277-83. PubMed ID: 15583734
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of kallikrein in human plasma.
McConnell DJ
J Clin Invest; 1972 Jul; 51(7):1611-23. PubMed ID: 4113391
[TBL] [Abstract][Full Text] [Related]
7. C1 inhibitor: the predominant inhibitor of plasma kallikrein.
Schapira M; de Agostini A; Colman RW
Methods Enzymol; 1988; 163():179-85. PubMed ID: 3237074
[No Abstract] [Full Text] [Related]
8. DX-88 and HAE: a developmental perspective.
Williams A; Baird LG
Transfus Apher Sci; 2003 Dec; 29(3):255-8. PubMed ID: 14572818
[TBL] [Abstract][Full Text] [Related]
9. Isolation and estimation of pure monkey serum kallikrein.
Maegraith BG; Onabanjo AO
J Physiol; 1969 Nov; 205(2):9P-10P. PubMed ID: 4982443
[No Abstract] [Full Text] [Related]
10. The pathogenesis of hereditary angioedema.
Davis AE
Transfus Apher Sci; 2003 Dec; 29(3):195-203. PubMed ID: 14572810
[TBL] [Abstract][Full Text] [Related]
11. C1 inhibitor: the main inhibitor of human plasma kallikrein.
Trumpi-Kalshoven MM; Kluft C
Adv Biosci; 1978 Jul; 17():93-101. PubMed ID: 90628
[No Abstract] [Full Text] [Related]
12. C3b inactivator of man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b.
Ruddy S; Austen KF
J Immunol; 1971 Sep; 107(3):742-50. PubMed ID: 4999095
[No Abstract] [Full Text] [Related]
13. The human plasma kallikrein-kinin system.
Colman RW; Girey GJ; Zacest R; Talamo RC
Prog Hematol; 1971; 7(0):255-98. PubMed ID: 4369309
[No Abstract] [Full Text] [Related]
14. [The kinins].
Paupe J
Ann Med Interne (Paris); 1969 Jan; 120(1):1-10. PubMed ID: 4974981
[No Abstract] [Full Text] [Related]
15. Colon kallikrein, its relation to the plasma enzyme.
Seki T; Nakajima T; Erdös EG
Biochem Pharmacol; 1972 May; 21(9):1227-35. PubMed ID: 4114146
[No Abstract] [Full Text] [Related]
16. Modulation of function of the activated first component of complement by a fragment derived from serum. I. Effect on early components of complement.
Gigli I; Kaplan AP; Austen KF
J Exp Med; 1971 Dec; 134(6):1466-84. PubMed ID: 5166612
[TBL] [Abstract][Full Text] [Related]
17. [The C1-inactivator of guinea pig serum: titration, purification and characterization of the inactivator].
Opferkuch W; Loos M; Ringelmann R
Z Med Mikrobiol Immunol; 1971; 156(2):194-207. PubMed ID: 4995249
[No Abstract] [Full Text] [Related]
18. [Developmental trends and results of the kallikrein-kinin research].
Werle E
Munch Med Wochenschr; 1973 Feb; 115(7):225-30. PubMed ID: 4540335
[No Abstract] [Full Text] [Related]
19. Novel therapies for hereditary angioedema.
Zuraw BL
Immunol Allergy Clin North Am; 2006 Nov; 26(4):691-708. PubMed ID: 17085285
[TBL] [Abstract][Full Text] [Related]
20. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor.
Schneider L; Lumry W; Vegh A; Williams AH; Schmalbach T
J Allergy Clin Immunol; 2007 Aug; 120(2):416-22. PubMed ID: 17559913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
